Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 8/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012676 | 0.85 | ELANE (0.36) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL12460196 | 0.84 | ACHE (0.38) | ACHEMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12993521 | 0.84 | ELANE (0.36) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL1581745 | 0.84 | ELANE (0.36) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL29427432 | 0.81 | KDM4E (0.43) | ELANEACHEMAPTL3MBTL1KDM4E | |
| SCHEMBL22648680 | 0.81 | ADORA3 (0.39) | ACHEMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18614387 | 0.79 | HSD17B10 (0.34) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL30697624 | 0.78 | ALDH1A1 (0.40) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL3661873 | 0.78 | ALDH1A1 (0.40) | FPR2ELANEPLAUF2KLKB1 | |
| SCHEMBL13738764 | 0.77 | MMP8 (0.45) | ELANEPLAUMAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| CN-115996932-A | New macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2023-04-21 | — | — | CN | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| EP-3042907-B1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) | 2021-01-13 | — | — | EP | disclosed |
| CN-104418866-B | Dgat1 inhibitor and its preparation method and application | 青岛黄海制药有限责任公司 | 2018-10-16 | — | — | CN | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-9809604-B2 | DGAT1 inhibitor and preparation method and use thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-07 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | QINGDAO HUANGHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042907-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Medshine Discovery Inc. (CN) | 2016-07-13 | — | — | EP | disclosed |
| CN-104418866-A | DGAT1 inhibitor, and preparation method and application thereof | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-03-18 | — | — | CN | disclosed |
| WO-2015024486-A1 | DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京明德新药研发股份有限公司 (CN) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272651-A1 | DGAT1 Inhibitor and Preparation Method and Use Thereof | DGAT1, DGAT2, LCAT | FPR2 3776/4885ELANE 2777/4885PLAU 1937/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | FPR2 3122/4885ELANE 4567/4885PLAU 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.